Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma

Journal of Veterinary Internal Medicine

Volumn 16, Issue 6, 2002, Pages 704-709

  Garrett, Laura D ^a   Thamm, Douglas H ^b   Chun, Ruthanne ^a   Dudley, Robert ^a   Vail, David M ^b  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer; Cyclophosphamide; Doxorubicin; Lymphosarcoma; UW 25; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ADMINISTRATION; FEMALE; LYMPHOMA; MALE; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; LYMPHOMA; MALE; PREDNISONE; SURVIVAL; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036836122     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2002.tb02411.x     Document Type: Review

References (36)

1. Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: A retrospective study. J Am Anim Hosp Assoc 2000:36:404-409.
2. Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997,11:333-339.
3. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
4. Chun R, Garrett LD, Vail DM Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma J Vet Intern Med 2000:14:120-124.
5. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
6. pot), argyrophilic nucleolar organizer regions (AgNOR). and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exp Hematol 1996;24:807-815.
7. Piek CJ, Rutteman GR, Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Vet Q 1999;21:44-49.
8. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
9. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994:205:1722-1728.
10. Carter RE Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation Doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987:23:587-596.
11. Cotter SM, Goldstein MA. Comparison of two protocols for maintenance of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1987;23:495-499
12. Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin's lymphomas. In: DeVita DT, Hellman S, and Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001:2256-2303.
13. Hahn KA, Richardson RC, Teclaw RF, et al. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma? J Vet Intern Med 1992;6:3-10.
14. World Health Organization. Report of a Consultation on the Biological Behavior and Therapy of Tumors of Domestic Animals. Geneva: World Health Organization: 1978.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-462.
16. Breslow N. A generalized Kruskal-Wallis test for comparing samples subject to unequal patterns of censorship. Biometrika 1970; 57:579-583.
17. Cox DR. Regression models and life tables. J Roy Stat Soc 1972; series B:187-190.
18. Siegel S. Nonparametric Statistics for the Behavioral Sciences. Tokyo: McGraw-Hill; 1959:96-104.
19. Simon RM. Design and analysis of clinical trials. In: DeVita DT, Hellman S, and Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001:521-537.
20. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997; 210:512-516.
21. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998; 12:465-470.
22. Postorino NC, Susaneck SJ, Withrow SJ, et al. Single agent therapy with adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 1989;25:221-225.
23. Moore AS, Ogilvie GK, Vail DM. Actinomycin D for reinduction of remission in dogs with resistant lymphoma. J Vet Intern Med 1994;8:343-344.
24. Van Vechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990;4:187-191.
25. Hammer AS, Couto CG, Ayl RD, et al. Treatment of tumorbearing dogs with actinomycin D. J Vet Intern Med 1994;8:236-239.
26. Lucroy MD, Phillips BS, Kraegel SA, et al. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med 1998;12:325-329.
27. Hohenhaus AE, Matus RE. Etoposide (VP-16): Retrospective analysis of treatment in 13 dogs with lymphoma. J Vet Intern Med 1990;4:239-241.
28. Golden DL, Langston VC. Uses of vincristine and vinblastine in dogs and cats. J Am Vet Med Assoc 1988;193:1114-1117.
29. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991;27:315-321.
30. Hahn KA, Fletcher CM, Legendre AM. Marked neutropenia in five tumor-bearing cats one week following single-agent vincristine sulfate chemotherapy. Vet Clin Path 1996;25:121-123.
31. Page RL, Macy DW, Thrall DE, et al. Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. Cancer Res 1988;48:288-290.
32. Ogilvie GK, Richardson RC, Curtis CR, et al Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1584-1587.
33. Arrington KA, Legendre AM, Tabeling GS, et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 1994;55:1587-1592.
34. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
35. Longo DL. Chemotherapy for advanced aggressive lymphoma: More is better . . isn't it? J Clin Oncol 1990;8:952-955.
36. MacEwen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981;178:1178-1181.